Eylea shows sustained improvements in BCVA vs. laser photocoagulation

Data from the phase 3 VIVID-DME trial indicate that aflibercept injection provided sustained improvements in best corrected visual acuity from baseline at 2 years compared with laser photocoagulation in patients with diabetic macular edema.Patients in the VIVID-DME trial were randomly assigned to either aflibercept (Eylea, Regeneron) 2 mg monthly, aflibercept 2 mg every 2 months or the comparator treatment of laser photocoagulation.

Full Story →